McKesson Corporation is a diversified healthcare services leader, tracing its roots back to 1833. The company partners with biopharma companies, care providers, pharmacies, manufacturers, and governments to deliver insights, products, and services aimed at improving healthcare accessibility and affordability. McKesson operates primarily in North America and Europe, focusing on pharmaceutical distribution, prescription technology solutions, and medical-surgical supplies. The company's competitive advantages lie in its scale, diversity of offerings, and established relationships across the healthcare ecosystem. McKesson faces competition from other distributors, service providers, and healthcare manufacturers.

• Employees: Approximately 51,000 worldwide (as of March 31, 2024)
• Geographic Footprint: Operations in North America and Europe
• Headquarters: Irving, TX
• Founded: 1833
• Number of distribution centers: 27 in the U.S.
• Revenue: $308.95 billion (FY2024)
• Key Subsidiaries/Brands: Health Mart, Ontada, ClarusONE Sourcing Services LLP

• CEO: Brian S. Tyler (since April 2019)
• CFO: Britt J. Vitalone (since January 2018)
• Chief Human Resources Officer: LeAnn B. Smith (since December 2022)
• Chief Strategy and Business Development Officer: Thomas L. Rodgers (since June 2020)
• Chief Legal Officer: Michele Lau (since January 2024)

Key executives have extensive experience in technology, finance, and healthcare. The CEO has been with McKesson since 2012, holding various leadership positions.

• Annual Revenue: $308.95 billion (FY2024)
• Net Income: $3.002 billion (FY2024)
• Total Assets: Not explicitly stated, but total liabilities and deficit is $67.443 billion.
• Key Financial Highlights: Revenue increased by 12% year-over-year; Diluted earnings per share decreased to $22.39 from $25.05 in the prior year; Recorded a provision for bad debts of $725 million related to the Rite Aid bankruptcy.

McKesson provides a wide array of products and services across its segments:

• Pharmaceutical Distribution: Distribution of branded, generic, specialty, biosimilar, and OTC pharmaceutical drugs, along with practice management, technology, and clinical support solutions.
• Prescription Technology Solutions: Medication access, affordability, and adherence solutions, including price transparency, benefit insight, and dispensing support services.
• Medical-Surgical Solutions: Medical-surgical supply distribution, logistics, and other services to healthcare providers.
• International: Distribution and services to wholesale, institutional, and retail customers in Canada and Europe, including retail pharmacies and technology solutions.

McKesson operates through four reportable segments:

• U.S. Pharmaceutical: Distributes pharmaceutical drugs and provides related solutions in the U.S.
• Prescription Technology Solutions: Offers medication access and affordability solutions.
• Medical-Surgical Solutions: Provides medical-surgical supply distribution and related services.
• International: Includes operations in Canada and Europe.

The U.S. Pharmaceutical segment accounted for the largest portion of revenue. The International segment's revenue was impacted by divestitures in Europe.

McKesson's strategy focuses on increasing operational efficiencies, focusing on core healthcare businesses, and enhancing its competitive position. Key initiatives include:

• Investing in new and existing distribution centers to increase scale and capacity.
• Investing in data and analytics, including AI, to improve productivity and enhance products and services.
• Pursuing strategic acquisitions and divestitures to optimize its portfolio.
• Focusing on growth in its integrated oncology service business and biopharma services business.

McKesson operates in highly competitive environments in North America and Norway. The healthcare industry is subject to increasing consolidation. Key competitors include Cencora, Inc. and Cardinal Health, Inc. in distribution and wholesaling. The company's retail businesses face competition from various global, national, regional, and local retailers. The pharmaceutical distribution environment is characterized by strong competition from various types of distributors and large payer organizations. The RxTS business faces competition from biopharma services companies, software firms, and internet-based companies.

• Litigation and Regulatory Risks: Exposure to costly legal disputes, government actions, and adverse publicity, particularly regarding opioid distribution.
• Company and Operational Risks: Risks related to cybersecurity incidents, technology system failures, and product non-conformance.
• Industry and Economic Risks: Impact of healthcare reform, competition, industry consolidation, and economic downturns.
• General Risks: Risks related to global climate change, and government regulations.